Observational study finds GLP-1 medications associated with increased risk of vision loss — Evidence Review

A new large study finds that people taking GLP-1 medications like Ozempic and Wegovy may have a slightly increased risk of a rare vision-threatening eye condition, a finding that generally aligns with related research. Most prior studies also report a modest but significant association between these drugs and ischemic optic neuropathy; see the Rutgers Institute for Health for more details.

• Multiple large-scale analyses and meta-analyses indicate a small but consistent increase in risk for ischemic optic neuropathy (ION) or similar ocular complications among GLP-1 receptor agonist users, including semaglutide and tirzepatide 2 3 6 8.
• While the absolute risk remains low, pharmacovigilance studies and case reports have repeatedly identified a signal for sudden vision loss events, particularly non-arteritic anterior ischemic optic neuropathy (NAION), linked to these medications 1 2 3.
• Some studies suggest the risk is higher in males and older adults, and the degree of risk may differ by drug formulation (e.g., Wegovy vs. Ozempic) and patient characteristics 3 4 6 7.

Study Overview and Key Findings

As GLP-1 receptor agonists (including Ozempic, Wegovy, Mounjaro, and Zepbound) become increasingly popular for both diabetes and weight management, questions about their long-term safety profile have grown in importance. The new study addresses a timely concern by investigating the potential link between these widely prescribed medications and a rare but serious eye condition that can cause sudden, often permanent vision loss. Notably, the study focuses on ischemic optic neuropathy in adults with type 2 diabetes—a group already at heightened risk for vascular complications—helping to clarify whether GLP-1 drugs add further ocular risk in this population.

Property	Value
Organization	Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers School of Public Health
Journal Name	Annals of Internal Medicine
Authors	Chintan Dave, Kamika Reynolds, Kimberly O'Malley, Jason Roy
Population	US adults ages 18 to 65 with Type 2 diabetes
Methods	Observational Study
Outcome	Risk of ischemic optic neuropathy associated with GLP-1 medications
Results	GLP-1 use linked to 3-4 additional cases of vision loss per 10,000 patients

Literature Review: Related Studies

To place these findings in context, we searched the Consensus database, which contains over 200 million research papers, using the following queries:

1. Ozempic vision loss risk
2. Wegovy sudden vision loss cases
3. GLP-1 receptor agonists ocular effects

Below, we summarize major themes and key findings from related studies:

Topic	Key Findings
Does GLP-1 therapy increase the risk of ischemic optic neuropathy?	• Multiple observational studies and meta-analyses report a modest but significant increase in risk of nonarteritic anterior ischemic optic neuropathy (NAION) or ischemic optic neuropathy with GLP-1 RA use 1 2 3 6 8. • Reported risk differences are small in absolute terms (e.g., 3-4 additional cases per 10,000; absolute risk around 0.09%) but consistent across diverse populations and settings 6 8.
Which patient groups are at greatest risk?	• Men and adults aged 50–65 appear to have higher risk for GLP-1–associated ischemic optic neuropathy, with the risk signal particularly strong for certain drug formulations (e.g., Wegovy) 3 4 6. • Patients with diabetes and pre-existing vascular risk factors may also be more susceptible to ocular events on GLP-1 therapy 1 9.
How do GLP-1 RAs affect other ocular outcomes?	• GLP-1 RA use is associated with a slightly increased risk of early-stage diabetic retinopathy and other retinal adverse events, though findings for late-stage or sight-threatening complications are mixed, with some studies showing reduced rates of blindness or severe complications 5 7. • Signals for other ocular adverse events—such as blurred vision, visual impairment, and retinal vascular events—have been observed, especially with semaglutide and lixisenatide 6 9.
Are these associations causal, and what mechanisms are proposed?	• Most studies emphasize that observed associations do not prove causality; confounding by indication and other patient factors may contribute to the risk 1 7 8. • Rapid glycemic shifts, underlying vascular disease, and drug-specific effects on blood flow or inflammation have been proposed as possible mechanisms for increased risk 1 6 9.

Does GLP-1 therapy increase the risk of ischemic optic neuropathy?

The new study's finding of a modestly elevated risk of ischemic optic neuropathy with GLP-1 medication use is strongly supported by recent observational analyses and meta-analyses. Multiple studies have detected a consistent signal linking semaglutide and related agents to NAION, both in real-world pharmacovigilance databases and pooled analyses across large populations.

• The absolute increase in risk is small, but the association persists after adjustment for confounders in several analyses 6 8.
• Case reports and post-marketing surveillance have repeatedly described incidents of NAION shortly after starting semaglutide 1 2.
• Meta-analyses estimate a 1.7-fold increased odds of NAION among GLP-1 RA users, with an absolute risk difference of approximately 0.04% 8.
• The new Rutgers study's results—3-4 extra cases per 10,000—fall squarely within the range reported by global pharmacovigilance and meta-analytic studies 6 8.

Which patient groups are at greatest risk?

Across the literature, the risk of GLP-1–associated ischemic optic neuropathy appears more pronounced in certain demographic and clinical groups. The Rutgers study and related research highlight both male sex and older age as important risk factors, and findings suggest drug formulation may influence risk.

• Men and individuals aged 50–65 are more likely to experience ischemic optic neuropathy on GLP-1 therapy, as seen in both case series and large database studies 3 4 6.
• Wegovy (higher-dose semaglutide) may carry a greater risk than Ozempic, with reporting odds ratios several times higher 3.
• Pre-existing vascular risk factors, including diabetes, hypertension, and dyslipidemia, may increase susceptibility to ocular complications with GLP-1 drugs 1 9.
• The new study's patient subgroup findings mirror these broader trends in the literature 3 4 6.

How do GLP-1 RAs affect other ocular outcomes?

Beyond ischemic optic neuropathy, research reveals a nuanced relationship between GLP-1 RA use and other eye diseases. While the drugs may increase early-stage diabetic retinopathy risk, there is less evidence for increased risk of the most severe, sight-threatening complications.

• Meta-analyses show GLP-1 RAs are linked to a higher risk of early-stage diabetic retinopathy and retinal events but may reduce the risk of late-stage complications compared to insulin 5.
• Some cohort studies report a lower incidence of blindness, neovascular glaucoma, or vitreous hemorrhage among GLP-1 RA users, even when the overall incidence of diabetic retinopathy is higher 7.
• Other ocular adverse events—blurred vision, visual impairment, macular edema, and retinal hemorrhage—have been reported more frequently with semaglutide and lixisenatide 6 9.
• The balance of ocular benefits and risks may depend on patient characteristics and the specific GLP-1 RA used 5 6 7.

Are these associations causal, and what mechanisms are proposed?

Despite repeated associations, most studies—including the new Rutgers analysis—caution that causality cannot be confirmed. Several possible explanations and mechanisms have been discussed in the literature.

• Observational and pharmacovigilance studies are subject to confounding by indication, as patients with diabetes and vascular risk factors may already be predisposed to ocular events 1 7 8.
• Rapid improvement in blood glucose, vascular effects of GLP-1 RAs, and changes in optic nerve perfusion are all hypothesized mechanisms for increased risk 1 6 9.
• Case reports often describe the timing of onset shortly after initiating GLP-1 therapy, but larger studies stress the need for randomized, prospective research to clarify causal links 1 8.
• The consistent, though small, risk signal across diverse data sources highlights the importance of ongoing pharmacovigilance and patient screening 2 6 8 9.

Future Research Questions

Although the current study and related literature provide important insights, several questions remain unanswered. Future research should aim to clarify causality, identify high-risk subgroups, and determine the optimal approach for monitoring and mitigating ocular risks in patients prescribed GLP-1 medications.

Research Question	Relevance
What is the mechanism linking GLP-1 receptor agonists to ischemic optic neuropathy?	Understanding the biological mechanism is critical for determining whether the association is causal and for developing preventive strategies 1 6 9.
Which patient subgroups are at highest risk for GLP-1-induced ocular complications?	Identifying individuals most susceptible to vision loss will allow for targeted screening and counseling, as risk appears to vary by age, sex, and comorbidities 3 4 6.
Does the risk of ischemic optic neuropathy differ between GLP-1 formulations (e.g. Wegovy vs Ozempic)?	Some studies suggest higher risk with certain formulations or dosages, but comparative safety data are limited and require confirmation 3.
What is the long-term risk of vision loss with GLP-1 receptor agonists in non-diabetic populations?	As GLP-1 medications are increasingly prescribed for obesity and weight management in people without diabetes, it is important to assess ocular risks in these groups 4 6.
What screening or monitoring protocols can reduce the risk of permanent vision loss in GLP-1 users?	Establishing evidence-based guidelines for ophthalmologic monitoring could help detect early symptoms and prevent irreversible outcomes, particularly in high-risk patients 1 7.